Leukotrienes
Leukotrienes - Related Videos
01:19
Antiasthma Drugs: Leukotriene Modifiers
0 Views •
2024
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body. Leukotriene modifiers work through two distinct mechanisms: 5-Lipoxygenase Inhibitors: Some drugs in this class, like zileuton (Zyflo), inhibit an enzyme called 5-lipoxygenase. This enzyme is crucial in synthesizing...
13:45
Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
0 Views •
Cited by 7 •
2010
This paper describes the methodology to determine the chemotactic response of leukocytes to specific ligands and identify interactions between the cell surface receptors and cytosolic proteins using live cell imaging techniques.
02:06
Allergic Reactions
0 Views •
2019
Overview We speak of an allergy when the immune system triggers a response against a benign foreign structure, like food, pollen or pet dander. These elicitors are called allergens. If the immune system of a hypersensitive individual was primed against a specific allergen, it will trigger allergic symptoms during every subsequent encounter of the allergen. Symptoms can be mild, such as hay fever, to severe, such as potentially fatal anaphylactic shock. Sensitization Is the First Step of an...
09:26
Cellular Lipid Extraction for Targeted Stable Isotope Dilution Liquid Chromatography-Mass Spectrometry Analysis
0 Views •
Cited by 6 •
2011
This protocol will demonstrate the extraction and analysis of free and esterified bioactive fatty acids from cells. Fatty acids are accurately quantified using stable isotope dilution, chiral liquid chromatography, electron capture atmospheric chemical ionization multiple reaction monitoring mass spectrometry (SID-LC-ECAPCI-MRM/MS).
FAQs
Leukotriene biosynthesis branches at leukotriene A4 (LTA4). After 5-lipoxygenase acts on arachidonic acid in an activated leukocyte, LTA4 can be converted into leukotriene B4 (LTB4) or into cysteinyl leukotrienes, including LTC4, LTD4, and LTE4. This branch point produces signals with different downstream effects, linking one precursor pathway to both leukocyte recruitment and airway responses.
Product identity influences the biological response. LTB4 serves as a chemotactic signal, whereas cysteinyl leukotrienes act through specific receptors to promote smooth-muscle contraction, mucus production, and increased vascular permeability. Thus, leukotrienes do not produce one uniform inflammatory effect; the downstream product and receptor-bearing target cell help determine whether the dominant outcome is cellular recruitment or tissue and airway change.
Specific receptor binding gives leukotriene signaling cellular selectivity. A leukotriene released during inflammation affects cells that carry the corresponding receptor, rather than every nearby cell equally. This arrangement connects biochemical production in activated leukocytes with distinct responses in target tissues, and it explains why receptors, as well as biosynthetic enzymes, are logical points for investigating or modifying inflammatory signaling.
Activation state is a key condition for pathway output because the described biosynthetic sequence occurs in activated leukocytes. A biology-focused analysis follows the pathway in order: arachidonic acid conversion by 5-lipoxygenase, formation of LTA4, branching toward LTB4 or cysteinyl products, and receptor engagement on target cells. This sequence distinguishes mediator production from the responses that follow receptor binding.
Leukotriene-related treatments can act at different levels of the pathway. Synthesis inhibitors target mediator production, whereas receptor antagonists interfere with the ability of leukotrienes to signal to target cells. Comparing these strategies separates reduced leukotriene formation from blocked mediator action, while connecting molecular intervention to asthma, allergic reactions, and other inflammatory disorders in which these signals are important.
In asthma and allergic reactions, cysteinyl leukotrienes are relevant to airway-related effects such as bronchoconstriction and mucus production. Increased vascular permeability adds a tissue-level inflammatory consequence. Studying these linked outcomes helps explain why leukotriene signaling matters in respiratory and inflammatory disorders, not merely as a biochemical pathway but as a regulator of changes that affect airway function and surrounding tissues.